Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 8 621-625, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Serum androgens and prostate cancer

AM Nomura, GN Stemmermann, PH Chyou, BE Henderson and FZ Stanczyk
Japan-Hawaii Cancer Study, Kuakini Medical Center, Honolulu 96817, USA.

It is suspected that male hormones are associated with the risk of prostate cancer. To test this hypothesis, we conducted a nested case-control study in a cohort of 6860 Japanese-American men examined from 1971 to 1975. At the time of examination, a single blood specimen was obtained, and the serum was frozen. After a surveillance period of more than 20 years, 141 tissue-confirmed incident cases of prostate cancer were identified, and their stored sera and those of 141 matched controls were assayed for total testosterone, free testosterone, dihydrotestosterone, 3-alpha-androstanediol glucuronide, androsterone glucuronide, and androstenedione. Odds ratios for prostate cancer, based on quartiles of serum hormone levels, were determined using conditional logistic regression methods. The odds ratios for the highest quartiles were 1.37 (95% confidence interval, 0.73-2.55) for 3-alpha-androstanediol glucuronide and 1.24 (95% confidence interval, 0.62-2.47) for androstenedione, but none of the differences was statistically significant. The results were unremarkable for the other four hormonal measurements. In addition, the patients and controls were compared by hormonal ratios (i.e., total testosterone:dihydrotestosterone), but the results were also unremarkable. The findings of this study indicate that none of these androgens is strongly associated with prostate cancer risk.

This article has been cited by other articles:

				E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]

				I. Boger-Megiddo, N. S. Weiss, M. J. Barnett, G. E. Goodman, and C. Chen V89L Polymorphism of the 5{alpha}-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 286 - 291. [Abstract] [Full Text] [PDF]

				C. Chen, N. S. Weiss, F. Z. Stanczyk, S. K. Lewis, D. DiTommaso, R. Etzioni, M. J. Barnett, and G. E. Goodman Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1410 - 1416. [Abstract] [Full Text] [PDF]

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				A. H. Wu, A. S. Whittemore, L. N. Kolonel, F. Z. Stanczyk, E. M. John, R. P. Gallagher, and D. W. West Lifestyle Determinants of 5{{alpha}}-Reductase Metabolites in Older African-American, White, and Asian-American Men Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 533 - 538. [Abstract] [Full Text]

				C. Nagata, N. Takatsuka, H. Shimizu, H. Hayashi, T. Akamatsu, and K. Murase Effect of Soymilk Consumption on Serum Estrogen and Androgen Concentrations in Japanese Men Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 179 - 184. [Abstract] [Full Text]

				E. A. Platz, E. B. Rimm, W. C. Willett, P. W. Kantoff, and E. Giovannucci Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health Professionals J Natl Cancer Inst, December 20, 2000; 92(24): 2009 - 2017. [Abstract] [Full Text] [PDF]

				M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]

				T. Shaneyfelt, R. Husein, G. Bubley, and C. S. Mantzoros Hormonal Predictors of Prostate Cancer: A Meta-Analysis J. Clin. Oncol., February 14, 2000; 18(4): 847 - 847. [Abstract] [Full Text] [PDF]

				P. G. Febbo, P. W. Kantoff, E. A. Platz, D. Casey, S. Batter, E. Giovannucci, C. H. Hennekens, and M. J. Stampfer The V89L Polymorphism in the 5{{alpha}}-Reductase Type 2 Gene and Risk of Prostate Cancer Cancer Res., December 1, 1999; 59(23): 5878 - 581. [Abstract] [Full Text] [PDF]

				R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731. [Abstract] [Full Text] [PDF]

				S. J. Santner, B. Albertson, G.-y. Zhang, G.-h. Zhang, M. Santulli, C. Wang, L. M. Demers, C. Shackleton, and R. J. Santen Comparative Rates of Androgen Production and Metabolism in Caucasian and Chinese Subjects J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2104 - 2109. [Abstract] [Full Text]